Biotech RadarJobs updated

COMPANY

Constant Therapeutics

constanttherapeutics.com ↗

Clinical Phase 2

Profile checked Oct 10, 2026

Keywords: DMD-Associated Dilated Cardiomyopathy Ischemic Stroke talfirastide

2Trials (company is sponsor)

Timeline

  1. Trial start 2: Phase 2 Study of TXA127 in Post-ischemic Stroke Patients source ↗
  2. Trial start Phase 2: TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy source ↗

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT06013839TXA127 in Non-Ambulant Patients With DMD CardiomyopathyPhase 2Unknown status (ClinicalTrials.gov)Aug 31, 20232024-08 (estimated)
NCT06135103Phase 2 Study of TXA127 in Post-ischemic Stroke Patients2Unknown status (ClinicalTrials.gov)Nov 26, 20232024-12 (estimated)
Feedback